DOCKET NO: 416272005200

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

CLAIMS

Claim 1 (Currently amended): A method of determining the <u>in vivo</u> metabolism of one or more sugars or fatty acids in an individual, said method comprising:

- (a) administering one or more compositions comprising one or more ²H-labeled sugars or ²H-labeled fatty acids to an individual;
- (b) obtaining one or more bodily tissues or fluids at one or more times from said individual; and
- (c) detecting the incorporation of said ²H <u>produced</u> from said one or more ²H-labeled sugars or ²H-labeled fatty acids <u>into in</u> water to determine the metabolism of said one or more sugars or fatty acids in said individual.

Claim 2 (Currently amended): The method according to claim 1, wherein said one or more compositions sugars comprise ²H-labeled glucose.

Claim 3 (Currently amended): The method according to claim 2, wherein said ²H-labeled glucose is ehosen selected from the group consisting of [6,6-²H₂]glucose, [1-²H₁]glucose, and [1,2,3,4,5,6-²H₇]glucose.

Claim 4 (Currently amended): The method according to claim 1, wherein said one or more compositions are administered by a technique ehosen selected from the group consisting of oral, gavage, intraperitoneal, intravascular, and subcutaneous administration.

Claim 5 (Original): The method according to claim 4, wherein said one or more compositions are administered orally.

Claim 6 (Original): The method according to claim 1, wherein said individual is a mammal.

Docket No.: 416272005200

Claim 7 (Currently amended): The method according to claim 6, wherein said mammal is ehosen selected from the group consisting of humans, rodents, primates, hamsters, guinea pigs, dogs, and pigs.

Claim 8 (Original): The method according to claim 7, wherein said mammal is a human.

Claim 9 (Currently amended): The method according to claim 1, wherein said one or more bodily tissues or fluids are chosen selected from the group consisting of blood, urine, saliva, and tears.

Claim 10 (Currently amended): The method of claim 1, wherein said one or more bodily tissues or fluids are chosen selected from the group consisting of liver, muscle, adipose, intestine, brain, and pancreas.

Claim 11 (Original): The method of claim 1, comprising the additional step of partially purifying said water.

Claim 12 (Original): The method of claim 11, comprising the additional step of isolating said water.

Claim 13 (Currently amended): The method according to claim 1, comprising the additional step of measuring ²H incorporation or a ratio of ²H incorporation into one or more chemical compositions ehosen selected from the group consisting of glucose, glycogen, glycerol-triglyceride, triglyceride fatty acid, proteins, and DNA.

Claim 14 (Original): The method according to claim 13, wherein said chemical composition is glucose.

Claim 15 (Original): The method according to claim 14, comprising the additional step of measuring endogenous glucose production.

Docket No.: 416272005200

Claim 16 (Currently amended): The method according to claim 14, comprising the additional step of measuring the <u>a</u> proportion of labeled glucose stored in tissue glycogen relative to said ²H-labeled sugar administered.

Claim 17 (Currently amended): The method according to claim 14, comprising the additional step of measuring the <u>a</u> proportion or rate of administered ²H-glucose undergoing glycolysis.

Claim 18 (Original): The method according to claim 13, wherein said chemical composition is glycogen.

Claim 19 (Original): The method according to claim 13, wherein said chemical composition is glycerol-triglyceride.

Claim 20 (Original): The method according to claim 19, comprising the additional step of calculating new triglyceride synthesis.

Claim 21 (Original): The method according to claim 13, wherein said chemical composition is triglyceride fatty acid.

Claim 22 (Original): The method according to claim 21, comprising the additional step of calculating new fatty acid synthesis.

Claim 23 (Currently amended): The method according to claim 13, comprising the additional step of calculating the <u>a</u> proportion or storage rate of labeled fatty acids stored in tissue relative to <u>a H-</u>labeled fatty acid administered.

Claim 24 (Currently amended): The method according to claim 1, comprising the additional step of calculating the <u>a</u> proportion or storage rate of administered <u>2H-</u>labeled fatty acids undergoing fatty acid oxidation.

Claim 25 (Original): The method according to claim 13, wherein said chemical composition is a protein.

Claim 26 (Original): The method according to claim 13, wherein said chemical composition is DNA.

Claim 27 (Currently amended): The method according to claim 24, comprising the additional step of calculating the <u>a</u> rate or amount of DNA synthesis.

Claim 28 (Currently amended): The method according to claim 1, further comprising calculating the \underline{a} rate or total amount of incorporation of said ${}^{2}H$ into said water.

Claim 29 (Currently amended): The method according to claim 13, further comprising calculating the <u>a</u> rate of or amount <u>of</u> incorporation of ²H into said one or more chemical compositions.

Claim 30 (Currently amended): The method according to claim 28, further comprising calculating the <u>a</u> rate of or amount <u>of</u> incorporation of ²H into said one or more chemical compositions.

Claim 31 (Currently amended): The method according to claim 1, wherein said water is detected by methods ehosen selected from the group consisting of gas chromatography/mass spectrometry, liquid chromatography-mass spectrometry, gas chromatography-pyrolysis-isotope ratio/mass spectrometry, gas chromatography-combustion-isotope ratio/mass spectrometry, cycloidal mass spectrometry, Fourier-transform-isotope ratio (IR)-spectroscopy, near IR laser spectroscopy, and isotope ratio mass spectrometry.

Claim 32 (Currently amended): The method according to claim 1, wherein said detecting step may be is accomplished by detecting one part ²H in 107 parts water.

Claim 33 (Canceled).

Response to Office Action of August 2, 2007

Claim 34 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism is used as a surrogate marker for FDA approval of drugs.

Claim 35 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism is used for the clinical management of patients.

Claim 36 (Canceled).

Claim 37 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism is chosen from further comprises identifying individuals at risk for insulin resistance and diabetes mellitus.

Claim 38 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism further comprises diagnosing high-fat diet-induced obesity.

Claim 39 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism further comprises identifying individuals at risk for high-fat diet-induced obesity.

Claim 40 (Currently amended): The method according to claim 1, wherein said metabolism determination determining of said metabolism further comprises the step ehosen from of monitoring the effects of interventions to prevent or reverse insulin resistance, diabetes mellitus and high-fat diet-induced obesity.

Claim 41 (Currently amended): The method according to claim 1, further comprising the further steps chosen from selected from the group consisting of diagnosing and treating wasting disorders.

Claim 42 (Currently amended): The method according to claim 1, further comprising the further steps chosen from selected from the group consisting of diagnosing and treating hypoglycemia.

Application No.: 10/701,990 8 Docket No.: 416272005200

Response to Office Action of August 2, 2007

Claim 43 (Currently amended): The method according to claim 1, <u>further</u> comprising the <u>further</u> steps ehosen from selected from the group consisting of diagnosing and treating glycogen storage disease.

Claims 44-66 (canceled).